This expanded partnership builds on our work with Feraheme and allows us to offer physicians a complementary, iron-based MRI contrast option for patients with brain tumors.” — Mike Zhou, CEO of ACA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results